Extra-skeletal Ewing’s sarcoma with EWSR1::ERG translocation of the breast: a case report

Weiping Li, Yingjun Wu, Xian Dong, Xinmin Qiu, Guangjuan Zheng, Yu ZhangDiagnostic 2025 · DOI

This case report, published in Diagnostic Pathology, details a rare and aggressive clinical encounter: the first molecularly confirmed case of primary extra-skeletal Ewing’s sarcoma (EES) of the breast harboring a rare EWSR1::ERG gene fusion. The study underscores the critical role of Next-Generation Sequencing (NGS) in diagnosing "small round blue cell tumors" when traditional protein-based markers provide conflicting results.

TL;DR

Researchers have documented the first case of primary breast Ewing’s sarcoma driven by the rare EWSR1::ERG translocation. Despite aggressive multimodal treatment, the tumor's rapid recurrence highlights the malignancy's severity and the necessity of NGS for definitive diagnosis in atypical anatomical sites.

What Problem Does This Paper Address?

Ewing’s sarcoma (ES) is a high-grade malignancy typically found in the bones of children and young adults. While it occasionally appears in soft tissues (extra-skeletal), primary involvement of the breast is exceptionally rare.

The diagnostic challenge lies in the "small round blue cell" morphology, which ES shares with several other cancers, including lymphoma, rhabdomyosarcoma, and small cell carcinoma. Furthermore, while ~90% of ES cases are driven by a specific EWSR1::FLI1 translocation, a small subset involves alternative partners like ERG. In rare locations like the breast, these atypical genetic drivers can lead to misdiagnosis if clinicians rely solely on standard imaging or immunohistochemistry (IHC).

Methods

The authors followed a standard clinical diagnostic pipeline but escalated to advanced molecular techniques when the initial results were ambiguous:

  • Clinical Imaging: Initial assessment via breast ultrasound (classified as BI-RADS 4B) and subsequent PET-CT.
  • Histopathology: Examination of surgical specimens using Hematoxylin and Eosin (H&E) staining to observe cellular architecture (e.g., pseudo-rosette formations).
  • Immunohistochemistry (IHC): A broad panel of protein markers (CD99, NKX2.2, FLI-1, ERG, etc.) was used to rule out other malignancies.
  • Next-Generation Sequencing (NGS): Used as the "gold standard" to identify the specific genetic translocation after IHC for the ERG protein returned a negative result.

Datasets

As this is a clinical case report, no large-scale datasets were generated. The study describes the clinical history, pathology, and molecular profile of a single 23-year-old female patient. The authors contextualize their findings by referencing existing literature on the roughly 12% of ES cases that occur in extra-skeletal sites.

Key Insights and Ideas

  • The "Rare-on-Rare" Diagnostic Trap: The case represents a rare tumor (EES) in an extremely rare location (breast) with a rare genetic variant (EWSR1::ERG). This combination makes the tumor a "diagnostic chameleon."
  • The IHC/NGS Discrepancy: Interestingly, the tumor tested negative for the ERG protein via IHC but positive for the EWSR1::ERG fusion via NGS. The authors propose several reasons for this:
  • Epitope Alteration: The fusion process might change the protein's shape, masking the site where the antibody is supposed to bind.
  • Low Abundance: The fusion protein might be expressed at levels below the detection threshold of standard IHC.
  • Cross-Reactivity of Markers: The tumor showed strong positivity for FLI-1 protein even though the FLI1 gene was not involved in the translocation. This suggests that FLI-1 IHC may not be specific enough to distinguish between different Ewing-family fusions.

Key Results

  • Molecular Signature: NGS identified a fusion between exon 7 of EWSR1 and exon 7 of ERG, confirming the diagnosis of Ewing’s sarcoma.
  • Aggressive Clinical Course: Despite a wide local excision (lumpectomy) with clear margins, followed by 12 cycles of chemotherapy (VAC/IE) and radiotherapy, the patient suffered two local relapses within just 15 months.
  • Treatment Resistance: The tumor demonstrated progressive enlargement even during second-line chemotherapy (VIP regimen), requiring a shift to an AE (doxorubicin + etoposide) regimen.

Limitations and Future Work

The primary limitation is the single-patient sample size, which is inherent to case reports of ultra-rare conditions. While this report establishes that EWSR1::ERG can occur in the breast, it cannot definitively determine if breast-based EES has a worse prognosis than bone-based ES, though the rapid recurrence in this case is concerning.

Future work would require multi-center retrospective studies to aggregate these rare cases. Such data could help determine if specific fusion partners (like ERG vs. FLI1) or specific anatomical sites require modified chemotherapy protocols to prevent the high rate of recurrence seen here.

Summary updated

Abstract

Our report establishes the first molecularly confirmed case of ES harboring the rare EWSR1::ERG translocation presenting as a primary breast mass. Primary breast ES can demonstrate significant morphologic and immunohistochemical overlap with other small round cell tumors. This case highlights that next-generation sequencing (NGS) is the gold standard for definitive diagnosis, as it reliably detects fusion partners-especially in rare tumors arising in uncommon locations.
BibTeX
@inproceedings{li2025extra,
  author = {Weiping Li and Yingjun Wu and Xian Dong and Xinmin Qiu and Guangjuan Zheng and Yu Zhang},
  title = {{Extra-skeletal Ewing’s sarcoma with EWSR1::ERG translocation of the breast: a case report}},
  booktitle = {Diagnostic},
  year = {2025},
  doi = {10.1186/s13000-025-01692-5},
}
Figure